Portal de investigação
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis
Autores da FMUP
Participantes de fora da FMUP
- Fernandes, SR
- Bernardo, S
- Saraiva, S
- Gonçalves, AR
- Santos, PM
- Valente, A
- Correia, LA
- Cortez-Pinto, H
Unidades de investigação
Abstract
Background Few patients can reach transmural remission in Crohn's disease (CD) with currently available therapies. Proactive optimization of infliximab (IFX) based on trough levels may potentially improve these results.Methods Retrospective cohort study including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 mu g/mL). A propensity score-matched analysis was performed to adjust for potential confounders.Results A total of 195 CD patients were included, 57.9% receiving proactive therapeutic drug monitoring. The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P = .004) with similar results in the propensity score-matched analysis (34.2% vs 17.1%; P = .025). In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95; 95% confidence interval, 1.44-6.06; P = .003).Conclusions Proactive optimization of IFX based on trough levels increases the rates of transmural remission in CD.
Dados da publicação
- ISSN/ISSNe:
- 1078-0998, 1536-4844
- Tipo:
- Article
- Páginas:
- 1974-1982
- DOI:
- 10.1093/ibd/izad272
- Link para outro recurso:
- www.scopus.com
Inflammatory Bowel Diseases Oxford University Press
Citações Recebidas na Scopus: 2
Documentos
- Não há documentos
Filiações
Keywords
- Crohn's disease; transmural remission; therapeutic drug monitoring
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Burden of Inflammatory Bowel Disease in Portugal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico (Inflammatory Bowel) . 2023
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Fernandes SR,Bernardo S,Saraiva S,Gonçalves AR,Santos PM,Valente A,Correia LA,Cortez H,Magro F. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis. Inflammatory Bowel Dis. 2023. 30. (11):p. 1974-1982. IF:4,900. (2).
